Latest News
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
9 November 2026 - Swedish fertility diagnostics company Spermosens AB (Spotlight Stock Market: SPERM) said on Monday it has signed a collaboration framework agreement with Australian fertility group Genea Pty Ltd to support an independent clinical st...
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
9 November 2026 - Biopharmaceutical company Janux Therapeutics Inc (Nasdaq: JANX) on Monday reported positive initial Phase 1 results for JANX011 in healthy volunteers, supporting plans to advance the investigational therapy into clinical studies for...
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
9 November 2026 - Genome research company Illumina Inc (NASDAQ: ILMN) announced on Monday that it has expanded its molecular residual disease (MRD) research portfolio with an early access programme for a new ultrasensitive duplex sequencing workflow ...
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
9 November 2026 - Biotechnology company Compass Pathways plc (Nasdaq:CMPS) said on Monday that it has completed its New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for COMP360, its investigational synthetic psilocyb...
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
9 November 2026 - Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) announced on Monday that it has entered into definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and dru...